Scarica l'app Stockscreener
0.8393
2.01%
-0.0129
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.8522
Aprire:
$0.8675
Volume 24 ore:
1.12M
Relative Volume:
0.71
Capitalizzazione di mercato:
$82.50M
Reddito:
-
Utile/perdita netta:
$-93.61M
Rapporto P/E:
-0.3978
EPS:
-2.11
Flusso di cassa netto:
$-71.16M
1 W Prestazione:
-14.73%
1M Prestazione:
+0.60%
6M Prestazione:
-12.71%
1 anno Prestazione:
-37.21%
Intervallo 1D:
$0.80
$0.89
Intervallo di 1 settimana:
$0.80
$0.985
Portata 52W:
$0.561
$2.11
Immunic Inc Stock (IMUX) Company Profile
Nome
Immunic Inc
Settore
Industria
Telefono
(332) 255-9818
Indirizzo
1200 AVENUE OF THE AMERICAS, NEW YORK
Confronta IMUX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.8363 | 83.75M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.60 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.07 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.49 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.68 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
303.40 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-25 | Iniziato | William Blair | Outperform |
| 2024-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-27 | Iniziato | B. Riley Securities | Buy |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2021-04-15 | Iniziato | Aegis Capital | Buy |
| 2021-03-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-08-07 | Ripresa | ROTH Capital | Buy |
| 2020-07-20 | Iniziato | BMO Capital Markets | Outperform |
| 2020-06-05 | Iniziato | Wedbush | Outperform |
| 2020-05-11 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-25 | Iniziato | ROTH Capital | Buy |
| 2019-07-11 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Immunic Inc Borsa (IMUX) Ultime notizie
What are the future prospects of Immunic Inc.July 2025 Intraday Action & Consistent Return Strategy Ideas - thegnnews.com
Immunic (IMUX) Q2 Loss Widens 25% - AOL.com
Momentum Screeners Rank Immunic Inc. in Top 5 TodayCapital Protection Trading Strategies Gain Interest - beatles.ru
H.C. Wainwright reiterates Buy rating on Immunic stock, citing positive MS data - Investing.com
H.C. Wainwright reiterates Buy rating on Immunic stock, citing positive MS data By Investing.com - Investing.com South Africa
Immunic, Inc. shares rise 3.21% premarket after Novartis' positive Phase III trial results for ianalumab in Sjögren's disease. - AInvest
William Blair Maintains Immunic(IMUX.US) With Buy Rating - 富途牛牛
Is Immunic Inc. stock a value trapInvestment Timing Signals - mustnews.co.kr
Technical signs of recovery in Immunic Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser
Will Immunic Inc. price bounce be sustainableFree Smart Trade Plans With Risk Protection - Newser
Intraday pattern recognizer results for Immunic Inc.Free Early Entry Tips With Low Risk Zone - Newser
Immunic reports promising Phase 2 data for lead drug candidate in progressive MSICYMI - Proactive financial news
Is a relief rally coming for Immunic Inc. holdersConservative Investment Setup and Risk Analysis - Newser
Immunic: Q2 Earnings Snapshot - Connecticut Post
Immunic, Inc. Advances Multiple Sclerosis Drug Trials - TipRanks
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Malaysian Reserve
Small cap wrap: Immunic, Nextech3D.ai, EDM Resources, Alvopetro… - Proactive Investors
Immunic Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Immunic CEO on strong Q2 progress with vidofludimus calcium trials for MS - Proactive financial news
Immunic CEO Discusses Strong Q2 Progress in Vidofludimus Calcium Trials for MS Treatment - AInvest
Immunic advances MS drug program with Phase 3 trials fully enrolled - Proactive Investors
Immunic Advances Phase 3 Trials and Financial Health - TipRanks
Immunic Q2 net loss widens, flags potential cash raise - AInvest
Biotech Immunic Q2 net loss widens, flags need to raise cash - MarketScreener
Immunic, Inc.: A High-Potential Biotech Play in the MS and GI Therapeutics Space - AInvest
EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Ariva
Immunic (IMUX) to Release Quarterly Earnings on Thursday - Defense World
Immunic, Inc. shares fall 1.43% after-hours as ImmunoPrecise Antibodies Ltd. reports earnings miss and auditor raises 'going concern' doubt. - AInvest
Immunic, Inc. shares fall 2.36% premarket after Sonnet BioTherapeutics' clinical trial data shows potential for SON-1010 in ovarian cancer. - AInvest
Immunic Inc. Stock Analysis and ForecastBreakout profit opportunities - Jammu Links News
When is Immunic Inc. stock expected to show significant growthMarket-crushing stock picks - Jammu Links News
How does Immunic Inc. compare to its industry peersMaximize gains with proven stock analysis - Jammu Links News
What is the dividend policy of Immunic Inc. stockMaximize returns with strategic portfolio planning - Jammu Links News
Should I hold or sell Immunic Inc. stock in 2025Invest confidently with real-time data analysis - Jammu Links News
What is the risk reward ratio of investing in Immunic Inc. stockSuperior profit margins - Jammu Links News
What are analysts’ price targets for Immunic Inc. in the next 12 monthsTrack high-yield stocks before they peak - Jammu Links News
What institutional investors are buying Immunic Inc. stockUnstoppable investment returns - Jammu Links News
What drives Immunic Inc. stock priceGain access to exclusive stock analysis - Jammu Links News
Is it the right time to buy Immunic Inc. stockProven strategies for superior portfolio growth - Jammu Links News
Is Immunic Inc. a growth stock or a value stockBuild wealth faster with consistent investment plans - Jammu Links News
Immunic, Inc. (NASDAQ:IMUX) Receives $7.50 Consensus Target Price from Brokerages - Defense World
Published on: 2025-08-03 05:26:52 - Jammu Links News
How volatile is Immunic Inc. stock compared to the marketTurbocharged investment results - Jammu Links News
How Immunic Inc. stock performs during market volatilityAccurate Forecast System with AI Support - Newser
Why is Immunic Inc. stock attracting strong analyst attentionBreakout Stocks Opportunities That Work - Jammu Links News
Why Immunic Inc. stock attracts strong analyst attentionDaily Chart Pattern Stock Forecast Shows Bullish Setup - beatles.ru
Immunic Inc Azioni (IMUX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):